the following example is for you reference.


Main Advantages: Full documents, best price, top quality

  

 

Technical details: 

  

 

Our Factory: 

  

 

Certificates:ISO, GMP

  

 

Our Service:

  

 

FAQ:
Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk, Denmark. Semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in treating type 2 diabetes.Novo Nordisk has completed six PChemicalbookhaseIIIa studies for its once-weekly injection of Sommarlutide and submitted a new drug registration application to the U.S. Food and Drug Administration (FDA) on December 5, 2016.An application for Marketing Authorization (MAA) has also been submitted to the European Medicines Agency (EMA).on the other hand, a once-daily oral formulation of sommarlutide is currently in phase III.